Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Janet Addison
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Rheumatology and Therapy
Related publications
GP2015: An Etanercept Biosimilar
BioDrugs
Medicine
Biotechnology
Pharmacology
Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
SAT0161 Preliminary Real World Data on Switching Patterns Between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry
Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar
Reumatologia
Rheumatology
Allergy
Immunology
A Real Concern or Just a Hype? – Evidence on Negative Clinical Consequences of Switching From Originator to Biosimilar Based on a Systematic Literature Review
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
SAT0199 Switch From Innovator Etanercept to Biosimilar Etanercept in Inflammatory Rheumatic Diseases: The Experience of Cochin University Hospital Paris-France.
P2.01-36 Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Decreased Flares of Rheumatoid Arthritis During the First Year of Etanercept Treatment: Further Evidence of Clinical Effectiveness in the "Real World"
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study
Arthritis Research & Therapy
